

Solid Tumor Pathology Requisition Form



Phone: 866.776.5907/Fax: 239.690.4237 | Email: Client.Services@NeoGenomics.com | Order Online: NeoLink.NeoGenomics.com

The following supplemental documentation is attached: **Pathology Report** **Insurance Information** Clinical Notes Relevant Test Results
Incomplete or missing data may result in delayed testing. **Bold fields are required.**

CLIENT INFORMATION

Account Number	Account Name	Phone #	Fax #
Street Address		City, State, Zip	
Req Completed By			Date
Ordering Physician	NPI#	Treating Oncologist/Physician	NPI #

PATIENT INFORMATION

First Name / Middle Initial / Last Name	Date of Birth MM/DD/YYYY / /	Biological Sex M F Unknown	Medical Record #
Street Address		City, State, Zip	Phone

BILLING INFORMATION ** Please include face sheet and insurance card **

Bill Type	Medicare	Insurance/Medicaid	Patient Self Pay	Split Billing: Client (Technical Component) and Insurance (Professional Component)
Hospital/Institution If billing charges to other Hospital/Facility: _____				
Patient Status at Time of Specimen Collection	Office/Non-Hospital	Hospital Outpatient	Hospital Inpatient, Date of Discharge / /	

CURRENT DIAGNOSIS AND RELEVANT CLINICAL HISTORY

Date of Original Diagnosis / /	Diagnosis	Primary ICD-10 Codes (C & D codes only)
Type	Breast Colorectal Gastric Melanoma Lung Ovarian Other: _____	
Stage	I II IIIA IIIB IV Unknown Note: _____	
Disease Status	Initial Diagnosis Progression R/R (Relapsed/Refractory)	

SPECIMEN INFORMATION

Specimen ID:	Block ID:	Fixative/Preservative:
Collection Date: / /	Collection Time: _____ AM PM	Retrieved Date: / /
Body Site: _____		
Streck Cell-Free DNA BCT® #: _____	Extract & Hold - ctDNA (see back for details)	Slides # _____ Unstained _____ Stained _____ H&E _____
Paraffin Block(s) #: _____ For molecular/NGS testing, if NeoGenomics retrieves multiple blocks, our pathologists will combine as necessary unless alternative instructions are provided		
Instructions: _____		
Predictive Marker Fixation (CAP/ASCO Requirement): *Indicated markers/profiles/panels require fixation information		
Cold ischemic (mins): _____ ≤ 1 hour Unknown	Fixative: 10% NBF Other: _____ Unknown	Fixation duration (hours): _____ 6-72 hours Unknown

TEST SELECTION

Pan-Solid Tumor CGP Tests	Tissue		Liquid				
	PanTracer™ Pro (DNA/RNA NGS with cancer-type directed IHC and ancillary testing based on the patient's tumor type)*	PanTracer Tissue (DNA/RNA)	PanTracer Tissue + HRD (DNA/RNA with HRD for Ovarian)	Neo PanTracer LBx (ctDNA)			
	Reflex to PanTracer LBx if tissue is insufficient for NGS						
	Add-On IHC with any PanTracer Tissue test – IHC tests will report separately			Tech Only			
	PD-L1 22C3†	FOLR1† (Ovarian)	HER2 Breast†	HER2† (Gastric Scoring)	Claudin18† (Gastric)	c-MET CDx for NSCLC†	
CancerTYPE ID for unknown/uncertain tumor type with Pathologist Directed NGS							
Disease-Specific Profiles	NeoTYPE® DNA & RNA - Lung (NGS – 50 genes with MSI and TMB) PD-L1 22C3 FDA for NSCLC† Global Tech Only Reflex to EGFR Mutation Analysis by PCR if tissue is insufficient for NGS			NeoTYPE DNA & RNA - Brain (NGS - 83 genes with MSI and TMB) Included: PD-L1 LDT IHC† Global Tech Only Add-On: MGMT Promoter Methylation Analysis			
NeoTYPE Disease-Specific Profiles (Multi-modal genomic profiling, DNA, FISH, IHC)	Tech Only – IHC and FISH						
	Breast	Cervical	Cholangiocarcinoma	Colorectal	Endometrial	Esophageal	Gastric
	GI Predictive	GIST & Soft Tissue	Head & Neck	HRR	Liver/Biliary	Lung	Melanoma
	Ovarian	Pancreas	Thyroid				
NeoTYPE Panel Modifications and Additions	Reflex to HER2 FISH if global HER2 IHC is 0 1+ 2+ (default) 3+ Do not reflex 2+ Opt out of HER2 Opt out of FOLR1 IHC (Ovarian Only) Reflex to NTRK 1-3 FISH Panel† instead of NTRK NGS if Pan-TRK IHC is positive or equivocal			RNA-Based Fusion Panels			
				Universal Solid Tumor NGS Fusion Panel			
				Sarcoma Comprehensive NGS Fusion Panel			
				NTRK NGS Fusion Panel (NTRK 1-3) NTRK & RET NGS Fusion Panel			
			Other: _____				

PHYSICIAN SIGNATURE & CONSENT

Ordering Physician Signature	Printed Name	Date
------------------------------	--------------	------

My signature certifies that (1) I am the patient's treating physician and am authorized under applicable law to order the tests on this test requisition, (2) each test ordered on this test requisition is medically necessary for the patient, (3) the results of each test will inform the patient's ongoing treatment plan and will be used in the management of the patient's care, (4) I explained to the patient the nature and purpose of each test to be performed pursuant to this test requisition, including, but not limited to, the purpose, capabilities, limitations, benefits and risks of each test, and the patient has had the opportunity to ask questions regarding each test and the collection, use, and disclosure of his/her samples and data, (5) I obtained from the patient all consents and authorizations required by applicable state and federal laws for the performance and billing of the ordered tests, which I will maintain on file and provide to NeoGenomics upon request, and (6) my decision to order these tests is not conditioned on, and was not influenced by, any remuneration, incentive, or other pecuniary benefit offered or provided by NeoGenomics or any third party, whether directly or indirectly.

Neo PanTracer LBx Liquid Biopsy Certification: If ordering Neo PanTracer LBx, the undersigned additionally certifies that he/she understands Medicare's medical necessity criteria for the Neo PanTracer LBx Liquid Biopsy test listed on the back of this form.

* Provided diagnosis will determine additional, appropriate testing for the case. See neogenomics.com/pantracer-portfolio#pro for associated add-ons by cancer diagnosis

Solid Tumor Pathology Requisition Form



Additional Billing Information: Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

- 1. Binding Service Order.** This Requisition Form is a contractually binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.
- 2. Third-Party Billing by NeoGenomics and Right to Bill Client.** Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state, or commercial health insurer or other third-party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event that NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten (10) days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

Neo PanTracer LBx Conditions for Medicare Coverage: Neo PanTracer LBx is a plasma-based, somatic comprehensive genomic profiling test (CGP) intended to assist physicians caring for patients with advanced solid tumors. In accordance with Medicare's MoIDX Noridian LCD L39230, testing is appropriate under the following circumstances:

- Patient has been diagnosed with a recurrent, relapsed, refractory, metastatic, or advanced solid tumor that did not originate from the central nervous system. Patients who would meet all the indications on the Food and Drug Administration (FDA) label for larotrectinib if they are found to have a neurotrophic receptor tyrosine kinase (NTRK) mutation may be considered to have advanced cancer, and
- For a patient who has been tested previously using a cell-free DNA/liquid biopsy test on the same genetic content, that patient may not be tested again unless there is clinical evidence that the cancer has evolved wherein testing would be performed for different genetic content. For example, in patients with cancer who were previously tested using a cell-free DNA/liquid biopsy test, if there is evidence for recurrence or progression despite response to a prior therapy, that recurrence or progression may represent a change in the tumor's molecular profile and may constitute a new clinical indication for additional genetic testing, and;
- Patient is untreated for the cancer being tested, or the patient is not responding to treatment (e.g., progression or new lesions on treatment), and
- The patient has decided to seek further cancer treatment with the following conditions:
 - The patient is a candidate for further treatment with a drug that is either FDA-approved for that patient's cancer, or has a National Comprehensive Cancer Network (NCCN) 1 or NCCN 2A recommendation for that patient's cancer, and
 - The FDA-approved indication or NCCN recommendation is based upon information about the presence or absence of a genetic biomarker tested for in the Neo PanTracer LBx, and
- Tissue-based, comprehensive genomic profiling (CGP) is infeasible (e.g., quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated) or specifically in NSCLC Tissue-based CGP has shown no actionable mutations.

A patient signed ABN is required if patient does not meet the coverage criteria. ABN is also required if ordering Neo PanTracer LBx concurrently with tissue testing that includes EGFR, BRAF, ALK, and ROS1.

Specimen Requirements & Usage : NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

PanTracer™ LBx: Peripheral blood: 2 x 10-mL Streck Cell-Free DNA BCT® tubes. Do not refrigerate. Special collection tubes and shipping requirements apply.

PanTracer LBx - Extract and Hold: ctDNA will be isolated from plasma and stored in freezer. PanTracer LBx analysis is not performed until the client test order is received. Processed samples will be retained for 30 days.

For molecular/NGS tissue testing, the following is requested: A single block for large resections where tumor is abundant, or up to 4 blocks from procedures with smaller specimens (e.g. Core biopsy, cell block). Only blocks from the same procedure and same tumor should be submitted together. Please call the Client Services team with any questions regarding specimen information.

All other tests: Refrigerate specimen if not shipping immediately and use cool pack during transport. A block is preferred for testing; please see individual test webpages for specimen requirements.

Please call our Client Services team with questions regarding specimen requirements or shipping instructions at 866.776.5907, option 3.

Please refer to [NeoGenomics.com](https://www.neogenomics.com) for specific details on each specimen.

PanTracer Tissue and NeoTYPE® DNA & RNA Profiles: If the sample is insufficient to produce either DNA or RNA results, the available results will be reported and alternate CPT® Codes may apply.

CancerTYPE ID® with reflex to pathologist directed NGS option, NGS Cancer Profile determined by the CancerTYPE ID® result. CancerTYPE ID® will be performed, reported, and billed separately by Biotheranostics, Inc. For comprehensive details about CancerTYPE ID® including test description, intended use, and limitations, visit [cancertypeid.com](https://www.cancertypeid.com).

Test Descriptions: For our complete test menu, turnaround times, specimen requirements, and more, please visit [NeoGenomics.com/Test-Menu](https://www.neogenomics.com/Test-Menu)